Faecal Matrix Metalloprotease-9 Is a More Sensitive Marker For Diagnosing Pouchitis Than Faecal Calprotectin – Results From a Pilot Study

Background. Potential non-invasive markers of pouchitis would have a great deal of significance within clinical practice. This study is aimed at assessing the diagnostic accuracy of faecal calprotectin and matrix metalloprotease-9 as potential markers in patients both with and without pouchitis. Patients and methods. Stool and blood samples were collected from 33 ileal pouch-anal anastomosis patients before a follow-up pouchoscopy. Biopsy samples were taken for histological purposes. The presence of cuffitis and stenosis was evaluated with an endoscopy. Calprotectin and matrix metalloprotease-9 were quantified with an enzyme-linked immunosorbent assay. Results. Pouchitis was detected in 30.3% of the patients. The levels of faecal calprotectin and matrix metalloprotease-9 increased significantly in patients with pouchitis. The sensitivity and specificity of matrix metalloprotease-9 was higher than that of faecal calprotectin. Only matrix metalloprotease-9 correlated significantly with the severity of pouchitis. Conclusions. Faecal matrix metalloprotease-9 has a high specificity in the diagnosis of pouchitis

Search for supersymmetry in events with a τ lepton pair and missing transverse momentum in proton-proton collisions at √s=13 TeV

A search for the electroweak production of supersymmetric particles in proton-proton collisions at a center-of-mass energy of 13 TeV is presented in final states with a $\tau$ lepton pair. Both hadronic and leptonic decay modes are considered for the $\tau$ leptons. Scenarios involving the direct pair production of $\tau$ sleptons, or their indirect production via the decays of charginos and neutralinos, are investigated. The data correspond to an integrated luminosity of 35.9 fb$^{-1}$ collected with the CMS detector in 2016. The observed number of events is consistent with the standard model background expectation. The results are interpreted as upper limits on the cross section for $\tau$ slepton pair production in different scenarios. The strongest limits are observed in the scenario of a purely left-handed $\tau$ slepton with a mass of 90 GeV decaying to a nearly massless neutralino, and correspond to 1.26 times the expected production cross section in the simplified model considered. Exclusion limits are also set in the context of simplified models of chargino-neutralino and chargino pair production with decays to $\tau$ leptons, and range up to 710 and 630 GeV, respectively

Search for physics beyond the standard model in high-mass diphoton events from proton-proton collisions at root s=13 TeV

A search for physics beyond the standard model is performed using a sample of high-mass diphoton events produced in proton-proton collisions at $\sqrt{s} =$ 13 TeV. The data sample was collected in 2016 with the CMS detector at the LHC and corresponds to an integrated luminosity of 35.9 fb$^{-1}$. The search is performed for both resonant and nonresonant new physics signatures. At 95% confidence level, lower limits on the mass of the first Kaluza-Klein excitation of the graviton in the Randall-Sundrum warped extra-dimensional model are determined to be in the range of 2.3 to 4.6 TeV, for values of the associated coupling parameter between 0.01 and 0.2. Lower limits on the production of scalar resonances and model-independent cross section upper limits are also provided. For the large extra-dimensional model of Arkani-Hamed, Dimopoulos, and Dvali, lower limits are set on the string mass scale $M_S$ ranging from 5.6 to 9.7 TeV, depending on the model parameters. The first exclusion limits are set in the two-dimensional parameter space of a continuum clockwork model

Event-by-event fluctuations of the kaon to pion ratio in central Pb+Pb collisions at 158 GeV per Nucleon

We present the first measurement of fluctuations from event to event in the production of strange particles in collisions of heavy nuclei. The ratio of charged kaons to charged pions is determined for individual central Pb+Pb collisions. After accounting for the fluctuations due to detector resolution and finite number statistics we derive an upper limit on genuine non-statistical fluctuations, perhaps related to a first or second order QCD phase transition. Such fluctuations are shown to be very small.Comment: 4 pages, 2 figure

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

<p>Abstract</p> <p>Background</p> <p>Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction and maintenance of clinical remission of CD. Our objective in this study is to report the nationwide, multicenter experience with IFX induction therapy for CD in Hungary.</p> <p>Methods</p> <p>During a 6-year-period, beginning in 2000, a total of 363 CD patients were treated with IFX as induction therapy (5 mg/kg IFX infusions given at week 0, 2 and 6) at eleven centers in Hungary in this observational study. Data analysis included patient demographics, important disease parameters and the outcome of IFX induction therapy.</p> <p>Results</p> <p>Three hundred and sixty three patients (183 women and 180 men) were treated with IFX since 2000. Mean age was 33.5 ± 11.2 years and the mean duration of disease was 6.7 ± 6.1 years. The population included 114 patients (31.4%) with therapy-refractory CD, 195 patients (53.7%) with fistulas, 16 patients (4.4%) with both therapy-refractory CD and fistulas, and 26 patients (7.2%) with steroid dependent CD. Overall response rate was 86.2% (313/363). A higher response rate was observed in patients with shorter disease duration (p = 0.05, OR:0.54, 95%CI:0.29-0.99) and concomitant immunosuppressant therapy (p = 0.05, OR: 2.03, 95%CI:0.165-0.596). Concomitant steroid treatment did not enhance the efficacy of IFX induction therapy. Adverse events included 34 allergic reactions (9.4%), 17 delayed type hypersensitivity (4.7%), 16 infections (4.4%), and 3 malignancies (0.8%).</p> <p>Conclusion</p> <p>IFX was safe and effective treatment in this cohort of Hungarian CD patients. Based on our experience co-administration of immunosuppressant therapy is suggested in patients receiving IFX induction therapy. However, concomitant steroid treatment did not enhanced the efficacy of IFX induction therapy.</p